Close Menu

NEW YORK (GenomeWeb) – Sweden-based antibody array diagnostics firm Immunovia said today that it has started a multi-center prospective validation study of its Immray PanCan-d test for the early diagnosis of individuals at high risk for familial pancreatic cancer (FPC).

The longitudinal clinical study, called Panfam-1, will use the company's blood test to analyze 1,000 people at high risk for FPC over a period of three years. The subjects will be recruited at sites in the US and in Europe that offer FPC screening programs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.